JP2025516226A5 - - Google Patents

Info

Publication number
JP2025516226A5
JP2025516226A5 JP2024563620A JP2024563620A JP2025516226A5 JP 2025516226 A5 JP2025516226 A5 JP 2025516226A5 JP 2024563620 A JP2024563620 A JP 2024563620A JP 2024563620 A JP2024563620 A JP 2024563620A JP 2025516226 A5 JP2025516226 A5 JP 2025516226A5
Authority
JP
Japan
Prior art keywords
seq
approximately
pharmaceutical composition
composition according
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516226A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/066266 external-priority patent/WO2023212618A1/en
Publication of JP2025516226A publication Critical patent/JP2025516226A/ja
Publication of JP2025516226A5 publication Critical patent/JP2025516226A5/ja
Pending legal-status Critical Current

Links

JP2024563620A 2022-04-26 2023-04-26 ベネズエラウマ脳炎(vee)レプリコンを含む脂質ナノ粒子及びその使用 Pending JP2025516226A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335092P 2022-04-26 2022-04-26
US63/335,092 2022-04-26
PCT/US2023/066266 WO2023212618A1 (en) 2022-04-26 2023-04-26 Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Publications (2)

Publication Number Publication Date
JP2025516226A JP2025516226A (ja) 2025-05-27
JP2025516226A5 true JP2025516226A5 (cg-RX-API-DMAC7.html) 2026-05-11

Family

ID=86604603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563620A Pending JP2025516226A (ja) 2022-04-26 2023-04-26 ベネズエラウマ脳炎(vee)レプリコンを含む脂質ナノ粒子及びその使用

Country Status (9)

Country Link
US (1) US20250152737A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514328A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516226A (cg-RX-API-DMAC7.html)
KR (1) KR20250004731A (cg-RX-API-DMAC7.html)
CN (1) CN119317430A (cg-RX-API-DMAC7.html)
AU (1) AU2023262576A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255274A1 (cg-RX-API-DMAC7.html)
IL (1) IL316186A (cg-RX-API-DMAC7.html)
WO (1) WO2023212618A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202400648D0 (en) * 2024-01-17 2024-02-28 Uea Enterprises Ltd Protein replacement therapy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU744755B2 (en) 1997-11-12 2002-03-07 Brigham And Women's Hospital The translation enhancer element of the human amyloid precursor protein gene
WO2001055371A1 (en) 2000-01-28 2001-08-02 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP5225087B2 (ja) 2005-08-24 2013-07-03 ザ スクリプス リサーチ インスティチュート 翻訳エンハンサーエレメント依存性のベクター系
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN101622348A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
EP2225396A4 (en) 2007-11-30 2011-03-02 Univ Ohio State Res Found PROFILING AND SCREENING OF MICRO-RNA EXPRESSION IN PERIPHERAL BLOOD IN LUNG CANCER
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
JP2011517932A (ja) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病(ccl)と関連するマイクロrnaシグネチャーおよびその使用
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
US20120053224A1 (en) 2008-12-10 2012-03-01 Universitat Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
US20120264626A1 (en) 2009-05-08 2012-10-18 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
JP5965481B2 (ja) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ 皮膚t細胞リンパ腫(ctcl)の診断用マイクロrnaプロファイリング
WO2013033640A1 (en) 2011-09-01 2013-03-07 Allegro Diagnostics Corp. Methods and compositions for detecting cancer based on mirna expression profiles
US20140243240A1 (en) 2011-10-26 2014-08-28 Georgetown University microRNA EXPRESSION PROFILING OF THYROID CANCER
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016187531A1 (en) 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
KR20240144261A (ko) 2017-02-28 2024-10-02 사노피 치료적 rna
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2019023566A1 (en) * 2017-07-28 2019-01-31 Janssen Vaccines & Prevention B.V. METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
EP3723774A4 (en) 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
WO2020146700A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
DK3934673T3 (da) 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
JP2023535225A (ja) * 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子

Similar Documents

Publication Publication Date Title
Van Hoecke et al. mRNA in cancer immunotherapy: beyond a source of antigen
JP7755372B2 (ja) 脳中の転移乳癌および他の癌を処置するための方法および組成物
CN109476718B (zh) 编码免疫调节多肽的mrna的组合及其用途
ES2861001T3 (es) Polirribonucleótidos que codifican la familia del casete de unión a ATP y formulaciones de los mismos
Wang et al. Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses
JP6861516B2 (ja) Vlp−レプリコンを用いたクラスii mhc抗原の送達による癌免疫療法
JP2003525222A (ja) Il−12をコードする核酸分子の腫瘍内投与
DeFranciscis et al. Clinical applications of oligonucleotides for cancer therapy
AU2022422532A1 (en) Immunostimulatory mrna compositions and uses thereof
JP2023535225A5 (cg-RX-API-DMAC7.html)
CN109923123B (zh) 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
Mao et al. Targeting fibroblast activation protein with chimeric antigen receptor macrophages
Aghajani et al. Current approaches in glioblastoma multiforme immunotherapy
JP2024528052A5 (cg-RX-API-DMAC7.html)
WO2020037102A1 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
Copur Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
JP2024502295A5 (cg-RX-API-DMAC7.html)
Dixit et al. Functionalised ligand-based nanomaterial drug targeting approaches for colorectal cancer therapy
Chen et al. The role of TNC in atherosclerosis and drug development opportunities
Yang et al. Advances in lipid nanoparticles delivering genetic medicines for solid cancers
CN118147081A (zh) 原代nk car构建体和方法
WO2025140126A1 (en) Therapeutic ly6k mrna vaccine for cancer
de Oliveira Silva et al. New avenues for the treatment of immunotherapy-resistant pancreatic cancer
JP2024503000A5 (cg-RX-API-DMAC7.html)
JP5965838B2 (ja) 抗体およびその利用